SCHEMBL165396

SCHEMBL165396

O=S(=O)(c1ccc(F)cc1)c1nc(Cl)c2ccn(CCO)c2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.36
HDAC2 Q92769 1/20 0.36
HTR6 P50406 4/20 0.35
HDAC6 Q9UBN7 6/20 0.34
HDAC4 P56524 4/20 0.34
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
CASP1 P29466 1/20 0.32
CYP2C19 P33261 1/20 0.32
BRCA1 P38398 1/20 0.32
CASP7 P55210 1/20 0.32
FYN P06241 2/20 0.32
SRC P12931 2/20 0.32
FLT3 P36888 2/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163907 0.86 HDAC1 (0.35) HDAC1HDAC2HTR6HDAC6HDAC4
SCHEMBL164444 0.86 LRRK2 (0.38) HDAC1HDAC2HTR6HDAC6HDAC4
SCHEMBL165652 0.85 HTR6 (0.35) HDAC1HDAC2HTR6HDAC6HDAC4
SCHEMBL166059 0.83 MAPK1 (0.44) HDAC2KDM4EALDH1A1HPGDCASP1
SCHEMBL164315 0.82 HTR6 (0.37) HTR6KDM4EALDH1A1CYP1A2CYP2D6
SCHEMBL165127 0.81 GRIN2B (0.41) HDAC1HDAC2HTR6HDAC6HDAC4
SCHEMBL162439 0.76 MAPT (0.36) HTR6KDM4EALDH1A1CYP1A2CYP2D6
SCHEMBL169388 0.75 NTRK1 (0.42) CYP1A2CYP2C9CYP2C19
SCHEMBL165952 0.74 SRC (0.37) HDAC1HDAC2HTR6HDAC6HDAC4
SCHEMBL174845 0.71 HSP90AA1 (0.37) KDM4EALDH1A1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130303533-A1 AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-11-14 US disclosed
EP-2611809-A1 AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-07-10 EP disclosed
WO-2012030924-A1 AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303533-A1 AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF JAK3, JAK2, JAK1 HDAC1 2002/4885HDAC2 1689/4885HTR6 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.